| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.094 | 0.06 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | 0.069 | 0.06 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | BRD-K30748066 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.06 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.063 | 0.07 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.066 | 0.07 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.07 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.07 |